Medical Cannabis in Iowa
Once you're logged in, click the "ENTER" button found in the Course Summary box to the right. Your registration will then be confirmed.
Once you register for the course, you will have 180 days (approximately 6 months) from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.
On December 1, 2018, medicinal cannabis became available at five dispensaries located across the state of Iowa. This includes oils, creams and capsules that can be taken by Iowa residents who suffer from one of the eight qualifying medical conditions for medicinal cannabis treatment, such as cancer or untreatable pain. This presentation will discuss medical research and state-level reports related to cannabis medicinal uses and outcomes. Your patients will ask questions… do you have the answers?
Lucas Nelson, JD
General Manager, MedPharm Iowa, LLC
Lucas received his bachelors of business administration and accounting from James Madison University. In 2014, he received his law degree from Indiana University Maurer School of Law. In April 2017, He joined Kemin Industries and currently serves as the general manager of MedPharm Iowa.
Business Development Manager, Kemin Industries
Rebecca has worked for Kemin Industries for over 10 years. Various roles in global business intelligence researcher and technical business development associate. Rebecca’s current role is global business development manager. Prior to her time at Kemin Industeries, Rebecca was a research assistant with USDA. She received her bachelor’s degree in microbiology from Iowa State University and is currently enrolled in the University of Iowa Tippie College of Business.
Karry Smith, PhD, MPH
Founder and Medical Writer, Periphas Science Group
Dr. Karry Smith earned her Master of Public Health degree in Epidemiology and her PhD in Cell and Developmental Biology from the University of Iowa. Following two postdoctoral fellowships at the University of Iowa Carver College of Medicine (Biochemistry) and the Mayo Clinic (Physiology and Biomedical Engineering), Dr. Smith joined a contract research organization as a medical writer and consultant. In this position, she authors regulatory documents for pharmaceutical and device companies that support the approval of new therapies by the FDA. Dr. Smith has extensive experience teaching a wide range of science topics from biochemistry to genetics. She has given numerous talks about gene therapy/editing and precision medicine and has an interest in these and other health sciences topics as they relate to drug development and the future of medicine.
Copyright: All rights reserved. By viewing this activity, participants agree to abide by copyright and trademark laws, intellectual property rights, and all other applicable laws of the United States of America. No part of the syllabus may be used or reproduced in any manner whatsoever without written permission, except in the case of brief quotations embodied in articles or reviews.
Internet CME Policy: The Office of Continuing Medical Education (CME) at Des Moines University (DMU) is committed to protecting the privacy of its customers. DMU CME maintains its Internet site as an information resource and service for health professionals. DMU CME will keep your personal and credit information confidential when you participate in an Internet based program. Your information will never be given to anyone outside of the DMU CME program. DMU CME collects only the information necessary to provide you with the services that you request.
- 1.00 CE Contact Hour(s)